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Abstract
Eukaryotic microbial pathogens are major contributors to illness and death globally. Although 
much of their impact can be controlled by drug therapy as with prokaryotic microorganisms, the 
emergence of drug resistance has threatened these treatment efforts. Here, we discuss the 
challenges posed by eukaryotic microbial pathogens and how these are similar to, or differ from, 
the challenges of prokaryotic antibiotic resistance. The therapies used for several major eukaryotic 
microorganisms are then detailed, and the mechanisms that they have evolved to overcome these 
therapies are described. The rapid emergence of resistance and the restricted pipeline of new drug 
therapies pose considerable risks to global health and are particularly acute in the developing 
world. Nonetheless, we detail how the integration of new technology, biological understanding, 
epidemiology and evolutionary analysis can help sustain existing therapies, anticipate the 
emergence of resistance or optimize the deployment of new therapies.
The identification and use of antibiotics are some of the great medical achievements of the 
twentieth century, saving count-less lives by controlling the risk of infection from contagion, 
after injury, surgery or in immunosuppressed individuals. However, in only 80 years since 
the introduction of penicillin, resistance to a broad range of antibiotic drugs has become 
widespread, with the compounded risk from multidrug-resistant bacterial infections severely 
limiting treatment options. This has created justified concern and global attention, not only 
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in the medical community but also at government level, in the media and the general 
public1.
While predominantly applied to control prokaryotic microbial infections, the threat of 
disease from eukaryotic microorganisms has also been contained by therapeutic drugs — 
preventing or controlling disease caused by eukaryotic parasites and fungi in both a human 
and animal health setting. These represent some of the most important disease-causing 
agents (Table 1), particularly in the tropics, where the distribution of a pathogen is 
frequently linked to the distribution of the arthropods that act as disease vectors. Such 
vector-borne parasites include malaria (Plasmodium spp.) and kineto-plastid parasites 
(Trypanosoma cruzi, which causes Chagas disease; Trypanosoma brucei gambiense and T. b. 
rhodesiense, which cause human African trypanosomiasis (HAT); and 17 Leishmania spp., 
which cause a variety of cutaneous and visceral diseases). Other clinically important 
protozoan parasite species not considered here are transmitted either orally (Toxoplasma, 
Giardia and Entamoeba) or venereally (Trichomonas). Distinct from the many obligate 
eukaryotic unicellular parasites, opportunistic fungal pathogens are global in distribution and 
include Candida, Aspergillus spp., Cryptococcus and Pneumocystis spp.
The control of these eukaryotic pathogens has often involved therapies whose development 
predates the use of penicillin and which, in some cases, have unacceptable toxicity profiles2. 
Nonetheless, as with the rise of antimicrobial resistance in bacteria, resistance has emerged 
or is emerging against therapies targeting these eukaryotic microorganisms, with potentially 
devastating consequences for exposed populations. This has received far less attention than 
antibacterial resistance, despite some commonality in its underlying causes. Here, we detail 
how the control of eukaryotic microorganisms poses both similar and distinct challenges to 
that of bacterial pathogens, the drugs used to combat these pathogens, and the resistance 
mechanisms they are evolving. Finally, we discuss how the latest methodological approaches 
can anticipate the emergence of drug resistance and support new therapeutic approaches, 
either through the development of new drugs, the maintenance of existing therapies or 
through the use of alternative approaches to limit the spread of drug resistance.
Common challenges for the control of microbial pathogens
The challenges of controlling eukaryotic microbial pathogens share many similarities with 
bacterial infections. Both replicate more rapidly than their hosts, such that resistance can be 
selected in a relatively short timescale in a treated host population. This is exacerbated by 
inappropriate treatment profiles, leading to sub-curative exposure in the context of 
infection3. Problems of suboptimal dosing are particularly acute when applied to tropical 
parasites. For example, in the case of antimalarial therapies, up to 35% of drugs may be of 
low quality, or have packaging and labelling that is poor or may be falsified4. The lower 
than optimal concentrations of the active agent found in these low-quality antimalarial drugs 
can rapidly select for resistance in exposed populations, as can under-dosing resulting from 
self-prescription. For zoonoses, parasite selection in livestock populations treated with 
antimicrobials in a context in which there is poor supply chain management, fraudulent 
provision or cost barriers to optimal dosing can also lead to the emergence of resistance. For 
African trypanosomes, this represents a considerable threat, since up to 50 million doses of 
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trypanocides are used in sub-Saharan livestock annually, mainly as a prophylactic, and 
trypanocides represent 45% of animal health costs. Mirroring the situation with antibiotic 
use in veterinary contexts for bacterial infections, in which environmental contamination has 
generated substantial regulatory concern5, the agricultural use of fungicides might also 
contribute to the selection of azole-resistant Aspergillus fumigatus6.
A further similarity between bacterial and eukaryotic microbial pathogens is the 
phenomenon of persister populations7. Persisters are a subpopulation of pathogen that 
survives after exposure to a chemotherapeutic agent (or vaccine). They can then re-establish 
patent infection while remaining drug sensitive (reviewed in ref. 8). The state of persistence 
is not heritable and resistance is not due to genetic alterations directly linked to rendering a 
drug ineffective. Rather, persistence is a physiological state in which the pathogen actively 
responds to drug assault. Persistence ensures incidental survival but does not future-proof a 
pathogen as genetically heritable resistance would. However, the combination of a persister 
population and suboptimal drug dosage could provide a reservoir from which resistance can 
emerge and may even provide a population predisposed to evolve resistance more readily. 
An example of this relating to parasite dormancy is the resistance of Plasmodium falciparum 
to artemisinin (and other antimalarials such as mefloquine and atovaquone), which was first 
characterized by degrees of persistence followed by the emergence of genomic changes now 
causally associated with resistance (see later). Similarly, fungal infections (for instance with 
Candida albicans) that are associated with biofilms are a good example of persister 
populations analogous to those found in bacterial communities9–11. The duration of 
persistence can range from days (P. falciparum) to life-long (for example, C. albicans). 
Mechanisms of persistence vary — persistence may emerge spontaneously, possibly through 
stochastic changes in gene expression that prepare a population of pathogens for survival in 
varying environmental conditions (‘bet hedging’). This is best described in bacteria12 but is 
a phenomenon recently characterized in P. falciparum13. Furthermore, environmental 
signals may induce persistence, such as the nutrient starvation typically encountered by C. 
albicans in biofilms9,14.
Distinct challenges for the control of microbial pathogens
Although bacterial and eukaryotic microorganisms share common features with respect to 
their responses to drug exposure, there are also differences, with some challenges specific to 
the control of eukaryotic pathogens. First, eukaryotic microorganisms are more similar to 
their hosts than prokaryotic pathogens in terms of their biochemistry and metabolism, 
genetic composition, cell architecture and biology. Consequently, drugs targeting eukaryotic 
microorganisms must focus on differences from the eukaryotic norm, or particular 
specialisms of each pathogen group. This can restrict the cross-specificity of drugs to a point 
where there are distinctions in sensitivity between different apicomplexans (malaria, 
toxoplasma) or between the evolutionarily divergent trypanosomes, T. brucei spp. and T. 
cruzi. Comprising a different evolutionary kingdom, fungi have many differences from other 
eukaryotic microbial pathogens, again necessitating drugs to be developed for, and targeted 
to, a particular pathogen. This increases the challenges for drug development and inevitably 
constricts the new drug pipeline.
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Second, many eukaryotic microbial pathogens have evolved a parasitic lifestyle distinct from 
the opportunistic infections characteristic of most bacterial pathogens (but also fungi). The 
evolution of parasitism is often accompanied by the development of sophisticated immune 
evasion mechanisms, which increases the impact of the persister phenotypes described 
earlier. Specifically, bacteriostatic drugs can operate to clear infection in concert with the 
immune system15. However, drugs that generate cytostatic rather than cytocidal responses to 
infection with an immunosuppressive parasite can lead to recrudescence upon the removal of 
drug exposure. This, in turn, can predispose the population to selection for drug resistance. 
Similarly, adaptation to an intracellular lifestyle or particular body niche can protect 
parasites from drug exposure, a feature shared with some bacterial pathogens that have 
evolved to survive in cells rather than systemically (Legionella, Mycobacteria).
A third challenge relates to clinical diagnosis and screening for drug resistance in eukaryotic 
microbial pathogens16. In bacterial infections, screening for sensitivity to antibiotics is 
straightforward and routine. By contrast, eukaryotic parasites can require highly specialized 
growth media and considerable growth periods to determine their susceptibility or otherwise 
to potential drug therapies. Also, unlike bacterial susceptibility testing, in which a minimum 
inhibitory concentration (MIC) is determined, most parasitologists report half-maximum 
effective concentration (EC50) values without providing the Hill slope of the growth 
inhibition curve or calculating the 90% effective concentration (EC90) value. It is perfectly 
possible to obtain a resistant line with an identical EC50 to the susceptible isolate, yet that is 
still resistant owing to a shallower Hill slope. As a consequence, clinical diagnosis and the 
selection of appropriate clinical management can be slow or practically impossible in the 
context of all but the most specialized laboratories.
A fourth distinction from common bacterial infections is the economic challenge of treating 
diseases of the developing world. Diseases such as malaria, trypanosomiasis, leishmaniasis 
and cryptococcosis are common in the poorest parts of the world, where the economic 
capacity to develop or deliver treatments is very limited, often restricted to philanthropic and 
charitable donations or the concerted actions of intergovernmental agencies. This makes the 
threat of drug resistance even more acute since there is no financial incentive to develop new 
drugs to replace those to which resistance emerges. Nonetheless, some pharmaceutical 
companies are increasingly engaged in public–private partnerships, providing access to 
chemical compound collections and other resources helpful for discovering and developing 
new drugs for neglected tropical diseases. Excellent examples of this collaborative spirit 
include the Medicines for Malaria Venture (http://www.mmv.org/), the Drugs for Neglected 
Diseases initiative (http://www.dndi.org/) and the Tres Cantos Open Lab Foundation (http://
www.openlabfoundation.org/).
One route to limit the impact of drug resistance has been the exploitation of combination 
therapies for parasitic infections. This approach has proved useful for cancer therapy as well 
as for the treatment of tuberculosis, leprosy and viral infections such as HIV. Results have 
also been encouraging for parasitic infections; for example, through artemisinin combination 
therapy (ACT)17,18 to limit the emergence and spread of artemisinin-resistant malaria, and 
for trypanosomes, for which nifurtimox–eflornithine combination therapy19 is proving more 
robust than eflornithine-based therapy alone. However, combination therapies for parasitic 
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diseases require the availability of more than one effective drug or drug class, which is not 
always the case. Moreover, combination therapies have often been embraced only when 
resistance has already been detected to one of the frontline monotherapies, allowing 
multidrug-resistant parasites to be selected. In a situation like this, the use of drug 
combinations with different pharmacokinetics in plasma, as with artemisinin and 
piperaquine, can limit the emergence of resistance20. However, the cost of drugs for many 
parasites seen in the developing world can generate geographical discrepancies in the use of 
mono and combination therapies. In this scenario, the efficacy of combination therapies can 
be threatened by ingression of resistant parasites selected under monotherapy.
The final challenge for eukaryotic microorganisms that differs from many prokaryotic and 
viral pathogens has been the failure to formulate and use effective vaccines to prevent 
infection21. Malaria research has focused intensively on vaccine development without 
transformative success, whereas for African trypanosomes the immune evasion mechanism 
used by the parasite (antigenic variation) effectively renders vaccine approaches impossible. 
It has also proved challenging to produce safe, effective vaccines for other kinetoplastids, 
despite the widespread early use of ‘leishmanization’ for the cutaneous form of 
leishmaniasis, which has the risk of virulence in some individuals and 
immunosuppression22. Fungal pathogens have their greatest impact in 
immunocompromised individuals, rendering vaccines potentially less useful. At present 
there are no licenced fungal vaccines; nonetheless, there are promising developments for 
adhesion-like substance 3 (Als3)- and secreted aspartic protease 2 (Sap2)-based vaccines, 
although concerns have been raised over their univalency and the potential for C. albicans to 
circumvent their efficacy23.
Drugs and resistance mechanisms
Microorganisms have evolved numerous strategies to counteract cellular toxicity induced by 
diverse chemical stresses (xenobiotics, metals, reactive oxygen and reactive nitrogen species, 
and so on). Many of these generic defences have been co-opted for drug resistance. Figure 1 
summarizes the major therapeutic agents used to target malaria, kinetoplastid parasites and 
fungi, highlighting the dates of introduction and the appearance of resistance for each. The 
principal methods of resistance (Fig. 2) involve either reduction of the free drug level at the 
target site of action, alterations in the drug target, reducing its drug-binding affinity, or 
overexpression of the target, restoring its essential function. In the case of inhibition of a 
metabolic pathway, the essential end product can be produced either by induction of an 
alternative pathway or by upregulation of a salvage pathway to obtain an essential metabolite 
from the host. Downstream consequences of target inhibition include damage to DNA, 
proteins and lipids such that upregulation of repair pathways can also contribute to 
resistance. Unlike bacteria, acquisition of resistance genes by lateral gene transfer on 
plasmids has not been observed for protozoan parasites or fungal pathogens. In Table 2 we 
summarize the drugs used to treat eukaryotic microbial pathogens, their mode of action and 
mechanisms of resistance where known. Here, we highlight specific examples in which drug 
resistance or the threat of resistance challenges current control efforts.
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Malaria
The most successful antimalarial in history to date has been chloroquine, a 4-aminoquinoline 
derivative of quinine (itself the world’s first mass-distributed antimalarial), first synthesized 
in 1934 (ref. 24). Chloroquine was cheap and remained effective for decades. However, due 
to massive overuse and suboptimal compliance, resistance to chloroquine emerged in 
Southeast Asia in 1957 and in South America in 1960, and — by the mid-1980s — it was 
barely possible to use even in Africa25. Although disputed by some26, the leading candidate 
for resistance to chloroquine is the P. falciparum chloroquine resistance transporter PfCRT 
(ref. 27). However, despite reports that PfCRT functions as a chloride channel, a proton 
pump, an activator of Na+/H+ exchangers or a cation channel, the physiological function of 
PfCRT remains unclear28. Nonetheless, PfCRT is central to much antimalarial resistance, 
the precise profile of which is modulated by associated mutations in other genes.
Artemisinin and its derivatives are fast-acting but short-lived antimalarials that have been 
globally successful. In particular, ACTs (for example, artemether–lumefantrine, artesunate–
amodiaquine and dihydroartemisinin–piperaquine) were recommended by the World Health 
Organization in 2001 to ensure high cure rates of falciparum malaria and to reduce the 
spread of drug resistance to other frontline drugs. However, clinical resistance was 
confirmed in 2008 (ref. 29), characterized by a failure to clear parasites rapidly in patients 
around the Thai–Cambodian border30,31. Resistant parasites were characterized by 
transcriptomics32, large-scale whole-genome sequencing (WGS) of clinical isolates33,34 
and classical generation of resistant mutants by in vitro culture followed by WGS (ref. 35). 
This pinpointed multiple independent mutations in a gene encoding a Kelch propeller 
protein (KELCH13), which was then causally linked to resistance by reverse genetics36,37. 
Large-scale genomic epidemiological evidence suggests that artemisinin resistance is not as 
straightforward as the simple acquisition of mutations in kelch13. Indeed, nonsynonymous 
mutations in ferredoxin, apicoplast ribosomal protein S10, multidrug resistance protein 2 
and PfCRT also showed strong associations with artemisinin resistance29. These mutations 
appear to act as markers of a genetic landscape upon which artemisinin-resistance-
conferring kelch13 mutations are more likely to occur. These landscape mutations also 
correlate with the current geographical limits of artemisinin resistance29. This concept is 
further supported by additional genomic epidemiological evidence that demonstrates that 
many of the 20 or so mutations in kelch13 that have been implicated in the Southeast Asian 
manifestation of artemisinin resistance are also found in African P. falciparum isolates. 
However, these mutations are present at no greater frequency in the African strains than 
other P. falciparum genes, indicating a lack of selective pressure in that continent and that 
these strains lack the enabling genetic background observed in Southeast Asia38.
Kelch propeller domain proteins are subcellular organizers of multiprotein complexes, and 
indeed artemisinin-resistance-associated mutation of KELCH13 results in its reduced 
association with phosphatidylinositol-3-OH kinase (PI(3)K)39. Experimental overexpression 
of PI(3)K results in enhanced artemisinin resistance, and phosphatidylinositol 3-phosphate 
(PI(3)P) levels are predictive of resistance to artemisinin39. In addition, upregulation of the 
chaperonin complexes PROSC and TRiC, involved in the unfolded protein stress response in 
other eukaryotes, may contribute to artemisinin resistance32. Worryingly, resistance to some 
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of the various ACT regimens (involving lumefantrine, amodiaquine and PfCRT) is becoming 
evident40–43. However, the framework for the rapid evaluation of genome evolution in the 
face of drugs is in place and will hopefully swiftly indicate any further potential 
mechanisms.
Human African trypanosomiasis
The vast majority of reported cases of HAT are caused by T. b. gambiense, with less than 2% 
caused by T. b. rhodesiense44. Treatment involves either pentamidine or suramin for stage 1 
infection (before central nervous system involvement), whereas melarsoprol, eflornithine or 
nifurtimox/eflornithine combination therapy are used once the parasite crosses the blood–
brain barrier2, with the combination therapy reducing the duration of treatment regimens. 
Given the limited chemotherapeutic options for the treatment of HAT (Table 2), drug 
resistance could seriously compromise efforts to eliminate this epidemic disease as a public 
health problem44. Fortunately, resistance emergence for pentamidine has not been marked, 
despite continuous use of pentamidine since the 1940s, including a mass chemoprophylactic 
campaign in the 1950s in the then Belgian Congo. However, cross-resistance to pentamidine 
and melarsoprol, used for stage 2 of infection, is frequently observed. Melarsoprol is a 
trivalent melaminophenyl arsenical that has a propensity to react covalently with vicinal 
dithiols, including the parasite-specific dithiol, trypanothione45, to form a cyclic complex 
known as MelT (ref. 46). Melarsoprol has a high incidence of severe (lethal) toxicities and 
high rates of treatment failures have been reported in the Democratic Republic of Congo, 
Uganda, Angola and Sudan2. Although therapeutic failure does not necessarily equate with 
drug resistance, it appears that the high relapse rate in northwest Uganda is associated with 
reduced susceptibility to melarsoprol47,48. The recent report that the aquaglyceroporin 
AQP2 appears to function as a transporter for large drugs such as pentamidine and 
melarsoprol was surprising, given that aquaglyceroporins are channels facilitating the 
passive transport of water and small neutral molecules across cell membranes. Nonetheless, 
there is strong evidence that AQP2 is synonymous with the high-affinity pentamidine 
transporter (HAPT1)49, with a recent report indicating that pentamidine binds and inhibits 
the transporter and is then internalized via endocytosis50.
Chagas disease
For Trypanosoma cruzi, an intracellular parasite with a wide tissue tropism, infection has 
three phases: an acute phase associated with high parasitaemia; an asymptomatic 
(indeterminate) phase lasting anywhere between 10 to 30 years, during which parasitaemia 
is controlled by the immune response; and a chronic phase in about 30–40% of patients 
characterized by either cardiac disease or digestive disease (mega-oesophagus and 
megacolon). For treatment, benznidazole and nifurtimox have considerable activity in the 
acute phase51 and benznidazole also eliminates parasitaemia in the indeterminate and 
chronic phases of the disease52,53. However, a large multi-centre, randomized trial of 
benznidazole for chronic Chagas cardiomyopathy failed to significantly reduce cardiac 
clinical deterioration at up to 5 years follow-up53. Whether this is due to differences in drug 
susceptibility, pharmacokinetic/pharmacodynamic issues or the pathophysiology of the 
disease is not known. The results of two recent clinical trials with azole ergosterol inhibitors, 
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posaconazole and E1224 (a pro-drug of ravuconazole) have been equally 
disappointing52,54,55.
Visceral leishmaniasis
Treatment of visceral leishmaniasis, cutaneous and mucocutaneous leishmaniasis is limited 
to four main drugs: pentavalent antimonial complexes (sodium stibogluconate and 
meglumine antimonate); amphotericin B (as deoxycholate or liposomal formulations); the 
aminoglycoside paromomycin; and the alkylphosphocholine miltefosine56,57. Treatment 
varies according to geographical location, the immune status and other co-morbidities of the 
patient, and the disease classification58.
Of these treatments, widespread resistance to antimonial drugs is specific to South Asia and 
is not seen in sub-Saharan Africa or Brazil. Indeed, antimonial drugs are not recommended 
in India or Nepal owing to treatment failures starting in the 1990s and now reported to be as 
high as 60% in some regions59. This has been attributed to inappropriate treatment in an 
unregulated private health system or to the use of substandard antimonial drugs. However, 
South Asia is the only region where arsenic exposure and widespread antimonial resistance 
co-exist. Thus, environmental pollution and exposure of patients to arsenic in food and 
drinking water was proposed as an alternative hypothesis for the high rates of resistance60. 
Arsenic and antimony are both metalloids and selection of leishmania parasites for 
resistance to trivalent arsenic results in cross-resistance to trivalent antimony in vitro61, but 
its physiological relevance is uncertain. Chronic exposure of infected mice to arsenic in 
drinking water at environmentally relevant levels showed that it is possible to generate 
resistance to pentavalent antimony in vivo62. A retrospective clinico-epidemiological study 
identified a trend towards increased treatment failure in arsenic-exposed patients, but failed 
to reach statistical significance63.
Resistance to antimonials is multifactorial, and most of the mechanisms shown in Fig. 2 
have been implicated in Leishmania. Studies on experimental and clinical resistant isolates 
strongly support the hypothesis that trypanothione has a pivotal role in antimonial resistance. 
However, none of the following mechanisms are universal in resistant isolates. Decreased 
biological reduction of SbV to SbIII has been reported in resistant leishmania amastigotes64 
and two candidate ‘antimony reductases’ have been identified, although genetic65,66 and 
proteomic studies67,68 have not identified any changes in either TDR1 (ref. 69) or ArsC 
(ref. 70). The mechanism of uptake of SbV is not known, but modulation of expression of 
AQP1 affects SbIII susceptibility71–73. AQP1 copy number and expression levels correlate 
with susceptibility to SbIII in some, but not all, clinical isolates74,75. However, 
interpretation of this observation is complicated by the fact that AQP1 is located on 
chromosome 31, which is frequently trisomic or tetrasomic76 in these mosaic aneuploid 
parasites77. Upregulation of trypanothione and ancillary biosynthetic pathways has also 
been observed in genomic65,66 and metabolomic78,79 studies. MRPA is responsible for 
ATP-dependent efflux of SbIII as a thiol conjugate into membrane vesicles80 and a 
homodimeric ABC half-transporter (ABCI4) is one possible candidate for efflux across the 
plasma membrane81.
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Miltefosine, the only oral treatment for visceral leishmaniasis, was first approved for use in 
India in 2002. However, a decade on there is an increasing rate of clinical relapse82,83, 
which threatens to undermine the Kala-Azar Elimination Program in the Indian 
subcontinent. Stable resistance is readily generated in the laboratory with no cross-resistance 
to other anti-leishmanial drugs84,85.
Fungi
Several classes of antifungals are used clinically (Tables 1 and 2) — each with very different 
drug resistance profiles. The oldest antifungals are the polyene macrolide antibiotics, 
exemplified by amphotericin B, which remains a frontline choice for a broad-spectrum agent 
for fungal infections of unknown aetiology. Amphotericin deoxycholate is toxic to the 
kidneys, a side effect that is substantially ameliorated in lipid carrier formulations such as 
AmBisome, which also has potent anti-Leishmania activity. As with other eukaryotic 
pathogens, resistance to antifungal drugs has become an increasingly important clinical 
problem86,87. A few recognized cases exist of inherent resistance of certain fungi to 
specific antifungals, but mostly resistance is due to induced changes and mutations.
The imidazoles and more modern triazoles (collectively known as the ‘azoles’) constitute the 
main class of antifungals used in the treatment of infections. Various modifications of the 
triazole ring have generated a series of antifungals including fluconazole (used mainly in the 
treatment of Candida infections), and itraconazole, voriconazole, posaconazole, 
ravuconazole and the recently licenced isavuconazole, which have improved activity against 
Aspergillus and filamentous fungal species. These compounds have important differences in 
antifungal potencies, spectrum of activities, bioavailability, drug interactions and potential 
toxicity. For example, some patients treated with voriconazole suffer from photosensitivity 
and an elevated risk of skin carcinoma88. Other sterol inhibitors include the allylamines 
squalene epoxidase inhibitors and phenylmorpholine Erg24 D14 reductase and Erg2 D8-D7 
isomerase inhibitors that are used topically against dermatophytic infections for which 
clinical resistance is low.
Although some fungi such as Candida krusei are inherently azole resistant, multiply triazole-
resistant strains are now emerging89,90, as well as strains with cross-resistance to azoles and 
echinocandins, suggesting the emergence of concerning multidrug-resistant phenotypes in 
medically important fungi91. A threat from multi-azole-resistant strains of A. fumigatus 
may have arisen under the selective pressure of agricultural azole fungicides and subsequent 
transmission of azole-resistant strains to the clinic by spore dispersal92–95. The prevalence 
of these alleles is increasing in Europe and now in other parts of the world90,96,97. In 
Candida, mutants harbouring azole resistance have a fitness deficit98; however, multidrug-
resistant strains of Aspergillus do not seem to have markedly decreased fitness, implying 
that they may become stably represented in the environment.
The most recently developed major class of antifungal is the echinocandin antibiotics, of 
which caspofungin, micafungin and anidulafungin are used clinically. These have similar 
pharmaco-kinetic properties, although a new echinocandin (CD101; formerly biofungin) is 
in clinical trials and has improved stability in vivo and requires less frequent intravenous 
dosing. Echinocandins are fungicidal against Candida species and fungistatic or fungicidal 
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against Aspergillus, causing hyphal or bud tip lysis, but they are not efficacious against 
Pneumocystis jiroveci and some other species.
Hsp90-mediated changes in drug tolerance have also been implicated in determining 
echinocandin sensitivity99. Recently, multidrug azole/echinocandin resistance has been 
identified in fungi and this is particularly frequent in strains of C. glabrata, which is common 
in patients with haematological malignancies and solid tumours100,101. These multidrug-
resistant strains of C. glabrata can then only be treated with intravenous amphotericin, and 
since this agent has poor penetration into urine such infections are essentially untreatable.
Outstanding challenges and future prospects
We began by highlighting the similarities and differences between the emergence of drug 
resistance in prokaryotic and eukaryotic microorganisms. The control of emerging drug 
resistance in eukaryotic microbial pathogens also has similarities and distinctions from 
prokaryotic drug resistance, and the challenge for the future is to ensure best practice is 
employed for both groups. One effective mechanism to control the spread of drug resistance 
in bacterial pathogens is the application of appropriate antibiotic stewardship, applying the 
right drug at the right dose, at the right time, for the right duration. This approach operates 
effectively where there is well-regulated healthcare, effective and rapid screening, a 
selection of available drugs as contingency, and the necessary education and engagement 
between the patient and healthcare provider. Moreover, bacterial drug resistance is a global 
phenomenon in which resistance selected through poor stewardship in one geographical area 
may be contained by stringent practices in other areas, or combatted by an investment in new 
pharmaceutical development in wealthy countries. These containment measures are 
inevitably less effective where primary care is limited or too expensive, education is lacking 
or where the diseases involved do not have a direct impact in the developed world. As a 
consequence, the limitation of many eukaryotic pathogens to the poorer parts of the world 
makes a coordinated response to resistance emergence more difficult to achieve.
The drivers of the emergence of resistance are also more difficult to mitigate for many 
eukaryotic pathogens. As highlighted earlier, drug provenance and effective delivery is a 
considerable challenge in the developing world. Delivery is a particular challenge for 
prospective mass drug administration programmes, in which delivery to a population on a 
broad or local scale, if incomplete, can counteract its intention to contain the spread of 
existing resistance in target regions. A further complication in low- and middle-income 
countries is the effects of co-infection or malnutrition in populations treated with drugs 
targeting a particular pathogen (discussed previously102). Notably, the pharmacokinetic 
behaviour of drugs in malnourished individuals may be variable and unpredictable, leading 
to inadvertent under-dosing, which can drive resistance. When combined with 
immunosuppression induced by many parasites, or the hospital-induced immunosuppression 
of patients that become susceptible to fungal infection, drug concentrations that would clear 
infections in the context of a robust immune system may fall short in its absence. The 
ecological balance between distinct pathogens in patients with co-infections can also lead to 
unanticipated consequences, in which the removal of one pathogen can create a niche 
exploited by a distinct pathogen, or in which the normal interactions between pathogens 
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with each other, and with the immune system, is perturbed with drug pressure. The 
resistance mechanisms selected in drug-treated populations can also alter pathogen 
phenotypes with the risk of enhanced virulence.
Although the factors that drive drug resistance are well known, it remains essential to 
identify when drug resistance arises and to respond rapidly and effectively. As with health 
care, surveillance is a key challenge for diseases in the developing world, where populations 
may be inaccessible, reluctant to engage or where treatment failure can have multiple causes 
beyond the emergence of drug resistance. Moreover, resistance can show considerable 
variation among populations or in different geographical settings. Here, accurate and rapid 
detection is critical to understand resistance epidemiology and thereby the best treatment to 
deliver, but this can be difficult to achieve. Despite this, developments in field polymerase 
chain reaction (PCR) assays and next-generation sequencing permit the sensitive 
identification and tracking of emergent resistance, allowing earlier control responses than 
could be previously achieved. Hence, an integration of improved therapeutic delivery and 
treatment monitoring are critical control points to reduce the emergence of resistance, in 
tandem with the discovery of the relevant resistance mechanisms and the search for new 
drug therapies. These combined approaches span the individual scientific researcher to 
clinicians, to health agencies, governments and populations, all of which must be well 
integrated and alert, with effective and rapid communication between different levels to 
allow appropriate responses to be put into action if needed.
Fortunately, while drug resistance is emerging in many eukaryotic microbial pathogens, new 
tools and methodologies are being developed to (1) predict resistance mechanisms, (2) 
identify modes of drug action and potential escape pathways, and (3) understand pathogen 
biochemistry as a means of discovering possible new therapies. With respect to drug 
resistance, the advent of cost-effective and rapid genome resequencing allows signatures of 
selection to be identified103–106, while genome-wide RNA interference screens allow the 
mapping of resistance pathways107,108, and overexpression libraries109 can assist with 
drug target deconvolution through selective screens. These genetic tools are complemented 
by improvements in proteomics such that adaptations accompanying drug resistance can be 
pinpointed, providing information on resistance mechanisms, and potential diagnostic tools 
to detect the emergence of resistance110. Combined with the improved sensitivity and 
resolution of metabolomics analysis111, biochemical pathways can also be mapped in the 
context of drug exposure, allowing bypass mechanisms to be highlighted, if present. These 
each provide the essential early warning systems necessary to identify and combat the 
spread of drug resistance. Furthermore, certain combination therapies might offer novel 
transmission blocking strategies: very recently, resistance to the antimalarial atovaquone, a 
component (with proguanil) of the widely used and successful treatment marketed as 
Malarone, was further characterized. Resistance mutations that appear during the blood 
stage of infection localize to the mitochondrial protein cytochrome b, one of the few proteins 
encoded by the highly reduced Plasmodium mitochondrial genome. All atovaquone-
resistance mutations examined generate a deficient mitochondrion and a parasite that, while 
viable in the blood, is incapable of development in the mosquito and thereby cannot be 
transmitted112. Thus, despite the fact that resistance to atovaquone might arise repeatedly, 
each incident is isolated. Drugs that target cytochrome b could form part of combination 
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therapies that are self-limiting in terms of spread of drug resistance and may delay any 
transmission of resistance that arises to the drug it is partnered with.
Concluding remarks
Drug resistance in eukaryotic microorganisms is an increasing global problem that threatens 
the advances in health care made over the last 50 years. This mirrors the situation for 
bacterial and viral pathogens but is particularly acute given the abundance of eukaryotic 
pathogens in the poorest regions of the world. These countries have the least capacity to 
respond to the emergence of resistance through the development of new drugs, vaccines and 
diagnostics, while developed countries lack financial incentives to assist. Nonetheless, there 
are opportunities to respond to this threat owing to the distinct biology of many major 
eukaryotic pathogens, uncovered through basic research. Furthermore, many eukaryotic 
microorganisms are arthropod-borne diseases, such that targeting transmission can be a route 
to pathogen control not available for opportunistic pathogens. This can take the form of 
transmission-blocking vaccines or drugs targeting Plasmodium113, or the application of 
vector control measures such as insecticide-impregnated bed nets114, peri-domestic and 
indoor residual insecticide spraying114,115, tsetse traps116, or improved housing117. 
Sterile insect release is also a route to limiting the vector population and so restricting 
disease spread118,119. Eukaryotic microorganisms have also, like some bacterial pathogens, 
been found to show cooperative and social behaviours to optimize their establishment and 
transmission in their hosts or vectors120,121. These social responses can control parasite 
density or the development of transmission stages122–124, such that blocking or mimicking 
signals for communication or their transduction pathways provides new routes for limiting 
the impact of the pathogens using strategies that might be less susceptible to the emergence 
of resistance.
Whether or not new targets or approaches can be identified, there is a real need to optimize 
the delivery and deployment of drugs. Control of drug quality and distribution, and the 
supply of cost-effective drugs is crucial. Furthermore, the application of both 
epidemiological modelling and evolutionary theory to guide drug treatment policies is 
important in prolonging the lifespan of drugs and thereby maximizing the return on the 
considerable cost associated with developing and introducing a new drug. Targeted therapy 
as opposed to mass drug administration is key to limiting the emergence of resistance, or 
containing resistance when it is detected. This requires an integration of epidemiology, 
diagnosis, detection and supply chain control, as well as investment in a pipeline of new 
therapeutics ready to be deployed when resistance inevitably emerges. Only through slowing 
the emergence of resistance and accelerating new drug discovery will the control successes 
achieved against eukaryotic microbial pathogens be sustained.
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Figure 1. Timelines for emergence of drug resistance in parasitic diseases and fungi.
The solid bars represents the time from first widespread clinical use to the first year drug 
resistance was suspected or confirmed. The shading gradient indicates that certain drugs are 
still in use for particular indications or in specific geographical locations. NECT, 
nifurtimox–eflornithine combination therapy; VL visceral leishmaniasis. For fungal 
pathogens, insensitive or resistant strains have been identified shortly after the introduction 
of all of the major classes of antifungal agents. In the case of amphotericin B, there remains 
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very little resistance — and differences in sensitivity mainly reflect the relative inherent 
sensitivity of different species to this agent.
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Figure 2. Molecular mechanisms of drug resistance.
Eukaryotic microbial pathogens can exhibit drug resistance through reducing the overall 
intracellular concentration of the drug (less uptake, more efflux), by inactivating or failing to 
activate the drug, or by sequestering the drug away from its target. Resistance can also be 
mediated by reducing affinity of the drug for the target by mutation or by reducing the drug 
effect by overexpression of the target. Salvage and bypass pathways can also lower the 
overall impact of the drug action, as can the activation of pathways to repair any damage 
caused.
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Table 1
Diseases caused by eukaryotic microorganisms, their vectors and frontline treatment 
options.
Disease Pathogen group Vector Pathogen Frontline treatments*
Malaria Apicomplexan Anopheline mosquitoes P. falciparum Uncomplicated P. falciparum malaria: ACTs; artemether 
plus lumefantrine; artesunate plus amodiaquine; artesunate 
plus mefloquine; dihydroartemisinin plus piperaquine; 
artesunate plus sulfadoxine plus pyrimethamine.
Severe malaria: parenteral (or rectal, children <6 years) 
artesunate followed by oral ACT (i.m. artemether or i.m. 
quinine if artesunate unavailable).
P. vivax, P. ovale,
P. malariae or P.knowlesi
Blood stage infections: chloroquine (except in areas of 
chloroquine resistance); ACTs (except pregnant women and 
infants <6 months). Radical cure of liver (hypnozoite) 
infection: primaquine (close medical supervision with 
G6PD-deficient patients).
African trypanosomiasis Kinetoplastid Tsetse flies T. b. gambiense
(chronic form)
Haemolymphatic stage (no CNS involvement): pentamidine 
(i.m.).
CNS stage: nifurtimox (oral) and eflornithine (i.v.) 
combination therapy (NECT) (melarsoprol if NECT 
unavailable).
T. b. rhodesiense
(acute form)
Haemolymphatic stage (no CNS involvement): suramin 
(i.v.).
CNS stage: melarsoprol (i.v.).
American trypanosomiasis Kinetoplastid Triatomine bugs T. cruzi Benznidazole; nifurtimox.
Leishmaniasis Kinetoplastid Phlebotomine sandflies Visceral disease: 
Leishmania donovani, L. 
infantum
Visceral disease: Amphotericin B (as liposomal or 
deoxycholate complex, i.v.); miltefosine (oral, 
contraindicated in pregnancy); paromomycin (i.m.); sodium 
stibogluconate (SSG) or meglumine antimonate, parenteral 
(except India and Nepal); SSG plus paromomycin (East 
Africa).
Mucocutaneous disease: 
L. braziliensis, L. 
panamensis
Mucocutaneous: SSG (systemic).
Cutaneous disease: For 
example, L. major, L. 
tropica, L. mexicana, L. 
amazonensis
Cutaneous: SSG (intralesional); paromomycin (ointment); 
miltefosine.
Invasive candidiasis Fungal Opportunistic C. albicans, C. glabrata,
C. parapsilosis
Echinocandins; fluconazole; liposomal amphotericin B.
Aspergillosis Fungal Opportunistic A. fumigatus Voriconazole (amphotericin B formulations; caspofungin; 
micafungin; posaconazole; itraconazole).
Pneumocystis pneumonia Fungal Opportunistic Pneumocystis carinii Sulfamethoxazole–trimethoprim (clindamycin–primaquine).
Cryptococcal meningitis Fungal Opportunistic Cryptococcus neoformans Amphotericin B plus flucytosine; amphotericin B plus 
fluconazole.
Several of the parasitic pathogens are arthropod-transmitted, and in these cases the responsible vector is shown. Fungal pathogens are 
predominantly opportunistic. CNS, central nervous system; i.m., intramuscular; i.v. intravenous. *Second-line treatment options are given in 
parentheses. Data from the World Health Organization58,125–127 and other sources 57,128,129.
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Table 2
Modes of action and mechanisms of drug resistance in eukaryotic microorganisms.
Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
Plasmodium Chloroquine: 1957 (Southeast Asia); 
1960 (South America); mid-1980s 
(Africa)
4-Aminoquinoline Chloroquine 
interferes with the 
detoxification of 
haem into 
chemically inert 
haemozoin, 
resulting in 
accumulation of 
toxic chloroquine 
ferric haem 
complex and 
subsequent parasite 
lysis130.
K76T (ref. 27) 
mutation in a digestive-
vacuole-sited, ATP-
dependent, 10-
transmembrane-domain 
transporter PfCRT27; a 
range of more than 30 
different mutations 
might interact 
epistatically131–133. 
These stimulate the 
active efflux of 
chloroquine by mutant 
PfCRT or the passive 
efflux of diprotonated 
chloroquine133.
Other genes 
contributing to 
resistance include: the 
P. falciparum multidrug 
resistance transporter 1 
(PfMDR1) homologue; 
multipass 
transmembrane 
transporter CG2; and 
PfNHE1 and a sodium 
hydrogen antiporter 
also associated with 
quinine resistance134. 
The specific genetic 
background of the 
parasite and the range 
of mutations in genes 
other than PfCRT are 
also key to the 
manifestation of 
chloroquine 
resistance135.
An independent 
mutation in PfCRT 
(C350R) can reverse 
chloroquine resistance 
and also increase 
susceptibility of the 
parasite to other 
antimalarials 
(mefloquine, quinine 
and lumefantrine, but 
not piperiquine136).
The mutation N326D 
confers increased 
resistance to the 
antimalarial 
amodiaquine40.
Mefloquine: 1982 (Thailand) Quinoline-4-methanol Blockade of 
haemozoin 
formation and 
binding to 
phospholipids.
PfMDR1 is associated 
with mefloquine 
resistance137 but may 
also modulate 
chloroquine resistance 
through compensatory 
mutations that 
counteract PfCRT 
mutations that 
compromise parasite 
fitness138.
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
Artesunate, dihydroartemisinin and 
artemether: 2008 (Southeast Asia)29
Sesquiterpene lactone endoperoxides Form a carbon-
centred free radical 
or reactive 
electrophilic 
intermediate that 
alkylates a number 
of malaria 
proteins139 after 
activation by haem 
or free iron.
Dormancy resulting in 
an extended ring stage 
phase of development 
in the erythrocyte 
promotes resistance30–
32. Multiple 
independent mutations 
in a gene encoding 
KELCH13 confer 
resistance33–37. This 
results in its enhanced 
association with 
PI(3)K, which is 
subsequently 
underubiquitinated and 
accumulates along with 
its lipid product, 
PI(3)P.
The specific genetic 
background of the 
parasite and the range 
of mutations in genes 
other than kelch13 may 
also be key to the 
manifestation of 
resistance to 
artemisinin33.
Sulfadoxine/pyrimethamine: 1967 
(Thailand); 1980s (Africa)
Antifols Sulfadoxine: 
inhibition of 
dihydropteroate 
synthase (DHPS).
Pyrimethamine: 
inhibition of 
dihydrofolate 
reductase (DHFR).
Synergistic effect 
on thymidylate 
synthesis.
Decreased affinity of 
both drugs for their 
respective targets. 
Resistance to 
sulfadoxine involves 
DHPS point mutations. 
DHPS variant A437G 
confers moderate 
resistance, with the 
additional mutations 
S436F and A613S 
conferring high-level 
resistance140. 
Pyrimethamine clinical 
resistance involves 
DHFR point mutations 
at S108N in Africa and 
Southeast Asia. 
Additional mutations 
that confer high-level 
resistance are N51I and 
C59R (ref. 141). 
Increased GTP 
cyclohydrolase (copy 
number variations) 
enhances folate 
biosynthesis, 
compensating for loss 
of fitness141.
Proguanil High-level resistance to 
cycloguanil (a 
metabolite of 
proguanil) involves 
DHFR mutation of 
Ser108 to threonine. 
The triple mutations 
(C59R, S108N and 
I164L) confer cross-
resistance to both 
pyrimethamine and 
cycloguanil142.
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
Atovaquone (in combination with 
proguanil for prophylaxis or 
treatment)
Effective resistance to 
atovaquone involves 
one of a range of 
mutations in 
cytochrome b, most 
commonly Y268S. 
Other mutations 
associated with such 
resistance include 
I258M, Y268C, M133I 
and V259L143.
African trypanosomes Suramin Naphthylamine trisulfonic acid Mode of action 
unknown.
Laboratory-generated 
resistance mediated 
through the silencing of 
invariant surface 
glycoprotein (ISG75), 
the AP1 adaptin 
complex, lysosomal 
proteases and major 
lysosomal 
transmembrane protein, 
as well as spermidine 
and N-
acetylglucosamine 
biosynthesis108.
Pentamidine: clinical resistance is not 
significant
Diamidine Mode of action 
unknown.
Resistance is associated 
with loss of uptake on 
the P2 adenine/
adenosine 
transporter144, 
(AT1)145.
Cross-resistance 
between 
melaminophenyl 
arsenicals and 
diamidines is mediated 
by AQP2 (ref. 146). A 
chimaeric AQP2/AQP3 
gene is associated with 
cross-resistance to 
melarsoprol and 
pentamidine in 
laboratory-
generated49,146,147 
and clinical 
isolates148,149
Melarsoprol: treatment failures have 
been reported in the Democratic 
Republic of Congo, Uganda, Angola 
and Sudan2
Trivalent melaminophenyl arsenical Forms a cyclic 
complex with 
trypanothione 
known as MelT 
(ref. 46). Inhibits 
trypanothione 
reductase and 
probably other 
targets.
Resistance is associated 
with loss of uptake on 
the P2 adenine/
adenosine 
transporter144,145. A 
non-functional mutant 
has been identified in 
melarsoprol-resistant 
field isolates150.
See also AQP in 
pentamidine section.
Eflornithine (difluoromethylornithine) Fluorinated amino acid Mechanism-based 
inhibitor of 
ornithine 
decarboxylase, 
required for 
biosynthesis of 
polyamines and 
trypanothione.
Laboratory-generated 
resistance is due to loss 
of a non-essential 
amino acid 
transporter151,152. 
There is no detected 
resistance in T. b. 
gambiense, but there is 
inherent resistance in 
some clinical isolates 
of T. b. rhodesiense2.
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
Nifurtimox: poor efficacy as 
monotherapy, used in combination 
therapy with eflornithine (NECT)
Nitrofuran Prodrug activated 
by an oxygen-
insensitive 
mitochondrial 
nitroreductase 
(NTR)153 to form 
highly reactive drug 
metabolites154 that 
kill trypanosomes 
via unknown 
mechanisms155.
A genome-scale RNA 
interference screen 
identified NTR and a 
number of other genes 
possibly associated 
with NTR function108. 
NTR is also the key 
resistance determinant 
in laboratory-generated 
lines156,157, showing 
cross-resistance to 
fexinidazole, an oral 
nitroimidazole 
currently undergoing 
phase II/III clinical 
trials for HAT.
South American trypanosomes Benznidazole, nifurtimox: natural 
resistance in some T. cruzi isolates
Nitroheterocyclics Benznidazole is 
activated by 
mitochondrial 
NTR153,158 to 
form electrophilic 
drug 
metabolites159,160.
Drug efflux via an 
ABCG-like 
transporter161.
The NAD(P)H flavin 
oxidoreductase (old 
yellow enzyme) is 
downregulated in 
resistant lines162,163. 
However, this enzyme 
does not reduce 
benznidazole and only 
reduces nifurtimox 
under anaerobic 
conditions164.
Visceral leishmaniasis Sodium stibogluconate, meglumine 
antimonite: 1990s widespread 
resistance in India and Nepal, not 
widespread in sub-Saharan Africa or 
Brazil
Pentavalent antimonials SbV is reduced to 
SbIII to attack 
intracellular 
amastigotes. Likely 
to bind multiple 
targets including 
trypanothione 
reductase165,166, 
tryparedoxin 
peroxidase167 and 
CCHC zinc finger 
proteins166.
Selection for resistance 
to trivalent arsenic 
results in cross-
resistance to trivalent 
antimony in vitro61 
and in vivo62. 
Resistance is 
multifactorial through 
several mechanisms: 
(1) Decreased 
reduction of SbV to 
SbIII. (2) SbIII is taken 
up via an 
aquaglyceroporin73 
and modulation of 
expression of AQP1 
affects SbIII 
susceptibility71–73. (3) 
Elevated intracellular 
trypanothione 
levels168 or increased 
biosynthetic 
potential65,66,78,79. 
(4) Increased levels of 
tryparedoxin 
peroxidase confer 
resistance to SbIII (ref. 
169) and are found in 
clinical resistant 
isolates167. (5) MRPA 
(also known as PgpA 
or ABCC3), a member 
of the ATP-binding 
cassette (ABC) 
transporters, is 
amplified in some 
resistant lines170–172 
and sequesters SbIII in 
an intracellular 
vacuolar compartment 
close to the flagellar 
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
pocket80. (6) 
Chaperones and stress-
related proteins are 
upregulated67,68, 
potentially reducing or 
repairing cellular 
damage induced by 
antimonials173.
Paromomycin Aminoglycoside Inhibition of protein 
synthesis.
Added to World Health 
Organization essential 
medicines list in 2007. 
No notable clinical 
resistance. Laboratory-
derived resistant lines 
show decreased drug 
uptake and increased 
expression of 
ribosomal proteins174.
Miltefosine: 2012 (Indian 
subcontinent)
Alkylphosphocholine Miltefosine 
markedly perturbs 
lipid 
metabolism175–
177, but the targets 
and precise 
mechanism of 
action are not fully 
understood178.
Resistance involves 
either: loss-of-function 
mutations or 
underexpression of an 
aminophospholipid 
translocase 
(LdMT)179–181 or its 
regulatory subunit 
LdRos3 (ref. 182); or 
drug efflux by ABC 
transporters183,184.
Laboratory-generated 
resistant lines show 
alterations in lipid 
metabolism and gene 
expression85,185, but 
WGS in another study 
identified mutations 
only in the miltefosine 
transporter, pyridoxal 
kinase and an α-
adaptin-like 
protein176.
Amphotericin B (deoxycholate or 
liposomal formulation): no notable 
clinical resistance reported
Polyene macrolide antibiotics See below. Not applicable, as no 
notable clinical 
resistance has been 
reported.
Fungi Amphotericin B, amphotericin 
deoxycholate
Polyene macrolide antibiotics Binds ergosterol 
more avidly than 
human cholesterol, 
disrupting the 
semipermeable 
membrane and 
causing leakage of 
essential 
metabolites and the 
collapse of 
electrochemical 
gradients. Binding 
of low-density 
lipoprotein 
receptors and 
amphotericin-
mediated oxidative 
damage may also 
contribute.
Laboratory mutants 
with lower ergosterol 
content are less 
sensitive to 
amphotericin B, but are 
rare clinically. 
Aspergillus terreus is 
intrinsically less 
amphotericin sensitive 
but resistant strains 
have a normal 
ergosterol content, 
suggesting that 
membrane permeability 
may not be the only 
mechanism of 
amphotericin 
action186. Binding to 
ergosterol might 
contribute to its mode 
of action187.
Fluconazole, itraconazole, 
voriconazole, posaconazole, 
ravuconazole, isavuconazole
Azoles Bind haem groups 
and inhibit the 
P450-mediated 
Resistance involves the 
overexpression of drug 
efflux pumps and point 
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
14α-demethylation 
(Erg11p or Cyp51p) 
of lanosterol in the 
ergosterol 
biosynthetic 
pathway. Leads to 
impaired membrane 
permeability, 
membrane protein 
action and cell wall 
synthesis188.
mutations in the target 
ERG11/CYP51A gene 
product, along with 
promoter mutations in 
these genes189–191. 
Changes in the levels of 
three fungal main 
efflux pumps, Cdr1, 
Cdr2 and Mdr1, and 
mutations in the genes 
encoding the Tac1, 
Upc2, Pdr1 and Mrr1 
transcription factors 
required for efflux 
pump upregulation, 
represent major causes 
of decreased drug 
sensistivity192,193. 
This type of azole 
resistance can be 
acerbated by 
isochromosome 
formation and 
aneuploidy, which can 
increase the copy 
number of key 
resistance genes such 
as ERG11 and TAC1 
(refs 194–196). 
Interference with the 
RNA-polymerase-II-
interacting mediator 
complex can re-
sensitize Pdr1-
dependent regulation of 
drug efflux pumps197. 
Chaperone Hsp90 can 
mitigate against stress 
induced damage198 
and also contribute to 
multidrug resistance 
with echinocandins.
TR34/L98H and the 
more recently 
identified TR46/
Y121F/T289A alleles 
that confer clinical 
azole resistance are 
likely to have arisen 
from environmentally 
generated mutations.
Caspofungin, micafungin, 
anidulafungin, CD101 (formerly 
biofungin)
Echinocandins Cyclic hexapeptides 
with an antifungal 
bioactive lipid side 
chain that binds the 
fungal-specific 
β-1,3-glucan 
synthase Fks cell 
membrane proteins, 
disrupting cell wall 
integrity.
Resistance through 
point mutations in two 
major hotspots in the 
β-1,3 glucan synthase 
genes FKS1, and, in C. 
glabrata, FKS2 (refs 
86, 101, 199); these 
reduce drug 
binding57,181,182.
Upregulation of cell 
wall chitin can protect 
cell wall damage184–
186. Hsp90 chaperone 
can mitigate against 
stress-induced 
damage170.
Flucytosine (5-fluorocytosine) Fluoropyrimdines Converted to 5-
fluorouracil by 
cytosine deaminase, 
which becomes 
incorporated into 
Resistance results from 
mutations in the genes 
encoding cytosine 
permease transporter, 
cytosine deaminase, 
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Pathogen Drug and date of resistance 
reported
Drug class Mode of action Resistance mechanism
RNA, resulting in 
inhibition of DNA 
synthesis.
which converts 5-
fluorocytosine to 5-
fluorouracil, or the 
uracil phosphoribosyl 
transferase required to 
convert 5-
fluorocytosine into a 
substrate for nucleic 
acid synthesis200. 
Their impact is 
lessened by the use of 
5-fluorocytosine in 
combination therapy.
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